Harbin Medisan Pharmaceutical Co., Ltd.
Sembol: 002900.SZ
SHZ
10.31
CNYBugünkü piyasa fiyatı
62.4601
F/K Oranı
1.8348
PEG Oranı
3.19B
MRK Kapağı
- 0.01%
DIV Verimi
Harbin Medisan Pharmaceutical Co., Ltd. (002900-SZ) Finansal Tablolar
Bilanço
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1048.9 | 1293.9 | 1111.5 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 57.8 | 91.3 | 581.7 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 150.6 | 164.1 | 149.6 | ||||||||||||
balance-sheet.row.inventory | 0 | 208.8 | 161.2 | 156.5 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 28.2 | 4.5 | 9.5 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 1436.4 | 1623.7 | 1427.2 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1081.6 | 882.4 | 925.3 | ||||||||||||
balance-sheet.row.goodwill | 0 | 1.3 | 0.5 | 9.4 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 141.2 | 71.7 | 62.5 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 142.5 | 72.2 | 71.9 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 651.2 | 555.6 | 22.8 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 23.1 | 23.8 | 25.8 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 108.1 | 119.1 | 592.4 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 2006.5 | 1653.1 | 1638.3 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 0 | 3443 | 3276.8 | 3065.5 | ||||||||||||
balance-sheet.row.account-payables | 0 | 182.1 | 120.8 | 105.2 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 480.2 | 233.8 | 274.8 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 3.1 | 12.2 | 11.2 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 238.2 | 422.9 | 212.9 | ||||||||||||
Deferred Revenue Non Current | 0 | 79 | 83.9 | 89 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 7.9 | 188.3 | 2.5 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 449.7 | 627.1 | 412.4 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 8.3 | 5.1 | 8 | ||||||||||||
balance-sheet.row.total-liab | 0 | 1294.8 | 1224.8 | 949 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0 | 316.4 | 316.6 | 316.6 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 612.9 | 570.7 | 639.6 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 162.5 | 192.3 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1211.2 | 990.9 | 952.9 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2140.5 | 2040.7 | 2101.4 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 3443 | 3276.8 | 3065.5 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 7.7 | 11.3 | 15 | ||||||||||||
balance-sheet.row.total-equity | 0 | 2148.2 | 2052 | 2116.5 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 709 | 646.9 | 604.5 | ||||||||||||
balance-sheet.row.total-debt | 0 | 718.4 | 656.7 | 487.7 | ||||||||||||
balance-sheet.row.net-debt | 0 | -272.8 | -545.9 | -42.2 |
Nakit Akış Tablosu
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 26.5 | 349.7 | 26.6 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 106.6 | 99.1 | 79.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 11.7 | 95 | -1.4 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | -11.7 | -95 | 1.4 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 49.5 | 107.4 | -160.1 | |||||||||||
cash-flows.row.account-receivables | 0 | -10 | 49.6 | 49.1 | |||||||||||
cash-flows.row.inventory | 0 | 0.6 | 26.5 | 31.9 | |||||||||||
cash-flows.row.account-payables | 0 | 47.2 | -63.7 | -239.6 | |||||||||||
cash-flows.row.other-working-capital | 0 | 11.7 | 95 | -1.4 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | -37.9 | -568.8 | 49 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -89.2 | -73.9 | -145.9 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0.3 | 11.6 | 146.4 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -72 | -1113.7 | -1091 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 580.2 | 901.9 | 1437.6 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -4.1 | -145.9 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 419.3 | -278.2 | 201.3 | |||||||||||
cash-flows.row.debt-repayment | 0 | -270.2 | -269.5 | -230 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | -109.3 | -34.3 | -95.8 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 272.4 | 260.1 | 323.2 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -107.1 | -43.7 | -2.6 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 456.8 | -334.5 | 194.2 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 782.3 | 325.5 | 660 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 325.5 | 660 | 465.7 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 144.6 | -12.5 | -4.5 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -89.2 | -73.9 | -145.9 | |||||||||||
cash-flows.row.free-cash-flow | 0 | 55.4 | -86.5 | -150.4 |
Gelir Tablosu Satırı
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1186.8 | 1028.4 | 945.8 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 476.4 | 365.6 | 309.4 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 710.4 | 662.8 | 636.4 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | 2.4 | 110.5 | 46.5 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 693.4 | 679.6 | 765.2 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1169.7 | 1045.1 | 1074.6 | ||||||||||||
income-statement-row.row.interest-income | 0 | 27.9 | 28.3 | 11.8 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 22.9 | 22.6 | 13.8 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 2.4 | -17.5 | -1.9 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 2.4 | 110.5 | 46.5 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 2.4 | -17.5 | -1.9 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 22.9 | 22.6 | 13.8 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 108.7 | 106.6 | 122.9 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | 79 | 57.6 | 454.8 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | 81.4 | 40.1 | 452.9 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | 11.3 | 13.6 | 103.2 | ||||||||||||
income-statement-row.row.net-income | 0 | 73.7 | 30.2 | 351 |
Sıkça Sorulan Sorular
Nedir Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) toplam varlıklar?
Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) toplam varlıklar 3442984089.000 şeklindedir.
İşletmenin yıllık geliri nedir?
Yıllık gelir N/A'dur.
Firma kâr marjı nedir?
Firma kar marjı 0.582'dir.
Şirket serbest nakit akışı nedir?
Serbest nakit akışı -1.022'dur.
İşletme net kar marjı nedir?
Net kâr marjı 0.049'dir.
Firma toplam geliri nedir?
Toplam gelir 0.026'dur.
Nedir Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) net kar (net gelir)?
Net kar (net gelir) 73663110.000'dur.
Firmanın toplam borcu nedir?
Toplam borç 718376453.000'dir.
Faaliyet giderleri rakamı nedir?
İşletme giderleri 693357200.000'dır.
Şirket nakit rakamı nedir?
İşletme içi nakit 0.000'tir.